Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. (BBIO) Stock Overview

Explore BridgeBio Pharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.

BBIO●NASDAQ
HealthcareBiotechnology
$81.50
$1.44(1.74%)
U.S. Market opens in 58h 9m

BridgeBio Pharma, Inc. (BBIO)

Meyka AI Score

Z

Key Financials

Market Cap16B
P/E Ratio-22.91
EPS (TTM)$-3.74
ROE0.32%
Fundamental Analysis

AI Price Forecasts

1 Month$86.10
3 Months$91.93
1 Year Target$90.52

BBIO Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of BridgeBio Pharma, Inc. (NASDAQ: BBIO) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, BridgeBio Pharma, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of BBIO on the NASDAQ shows an RSI of 51.24, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $90.52 for the NASDAQ listing.

Key metrics behind BridgeBio Pharma, Inc.'s NASDAQ-traded stock include a P/E ratio of -22.91 and a market capitalization of 16B. Combined with our AI analysis, these give both institutional and retail investors a clear view of BBIO on the NASDAQ.

Price Performance (NASDAQ: BBIO)

1-Day Change
-1.74%
5-Day Change
1.70%
1-Month Change
-1.15%
3-Month Change
15.96%
6-Month Change
19.61%
Year-to-Date (YTD) Change
6.55%
1-Year Change
62.25%
3-Year Change
184.97%
5-Year Change
65.38%
All-Time (Max) Change
195.83%

Contact Information

https://www.bridgebio.com
650 391 9740
3160 Porter Drive, Palo Alto, CA, 94304

Company Facts

8,370 Employees
IPO DateJun 27, 2019
CountryUS
Actively Trading

Frequently Asked Questions